Literature DB >> 22692576

Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication.

Mudit Tyagi1, Michael Bukrinsky.   

Abstract

Failure of highly active antiretroviral therapy to eradicate the human immunodeficiency virus (HIV), even in patients who suppress the virus to undetectable levels for many years, underscores the problems associated with fighting this infection. The existence of persistent infection in certain cellular and anatomical reservoirs appears to be the major hurdle in HIV eradication. The development of therapeutic interventions that eliminate or limit the latent viral pools or prevent the reemergence of the viruses from producing cells will therefore be required to enhance the effectiveness of current antiretroviral strategies. To achieve this goal, there is a pressing need to understand HIV latency at the molecular level to design novel and improved therapies to either eradicate HIV or find a functional cure in which patients could maintain a manageable viral pool without AIDS in the absence of antiretroviral therapy. The integrated proviral genome remains transcriptionally silent for a long period in certain subsets of T cells. This ability to infect cells latently helps HIV to establish a persistent infection despite strong humoral and cellular immune responses against the viral proteins. The main purpose of this report is to provide a general overview of the HIV latency. We will describe the hurdles being faced in eradicating latent HIV proviruses. We will also briefly discuss the ongoing strategies aimed toward curing HIV infection.

Entities:  

Mesh:

Year:  2012        PMID: 22692576      PMCID: PMC3475336          DOI: 10.2119/molmed.2012.00194

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  233 in total

1.  The kappaB sites in the human immunodeficiency virus type 1 long terminal repeat enhance virus replication yet are not absolutely required for viral growth.

Authors:  B K Chen; M B Feinberg; D Baltimore
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

2.  The role of mononuclear phagocytes in HTLV-III/LAV infection.

Authors:  S Gartner; P Markovits; D M Markovitz; M H Kaplan; R C Gallo; M Popovic
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

3.  The SWI/SNF chromatin-remodeling complex is a cofactor for Tat transactivation of the HIV promoter.

Authors:  Tokameh Mahmoudi; Maribel Parra; Robert G J Vries; Steven E Kauder; C Peter Verrijzer; Melanie Ott; Eric Verdin
Journal:  J Biol Chem       Date:  2006-05-10       Impact factor: 5.157

Review 4.  HIV reservoirs and the possibility of a cure for HIV infection.

Authors:  S Palmer; L Josefsson; J M Coffin
Journal:  J Intern Med       Date:  2011-10-27       Impact factor: 8.989

5.  Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype.

Authors:  Deirdre D Scripture-Adams; David G Brooks; Yael D Korin; Jerome A Zack
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

6.  Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.

Authors:  Sifei Xing; Cynthia K Bullen; Neeta S Shroff; Liang Shan; Hung-Chih Yang; Jordyn L Manucci; Shridhar Bhat; Hao Zhang; Joseph B Margolick; Thomas C Quinn; David M Margolis; Janet D Siliciano; Robert F Siliciano
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

7.  Different sensitivity to apoptosis in cells of monocytic or lymphocytic origin chronically infected with human immunodeficiency virus type-1.

Authors:  Marcello Pinti; Priscilla Biswas; Leonarda Troiano; Milena Nasi; Roberta Ferraresi; Cristina Mussini; Jacopo Vecchiet; Roberto Esposito; Roberto Paganelli; Andrea Cossarizza
Journal:  Exp Biol Med (Maywood)       Date:  2003-12

8.  Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough.

Authors:  Yefei Han; Yijie B Lin; Wenfeng An; Jie Xu; Hung-Chih Yang; Karen O'Connell; Dominic Dordai; Jef D Boeke; Janet D Siliciano; Robert F Siliciano
Journal:  Cell Host Microbe       Date:  2008-08-14       Impact factor: 21.023

9.  Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activation.

Authors:  Hung-Chih Yang; Sifei Xing; Liang Shan; Karen O'Connell; Jason Dinoso; Anding Shen; Yan Zhou; Cynthia K Shrum; Yefei Han; Jun O Liu; Hao Zhang; Joseph B Margolick; Robert F Siliciano
Journal:  J Clin Invest       Date:  2009-10-01       Impact factor: 14.808

10.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation.

Authors:  Nicolas Chomont; Mohamed El-Far; Petronela Ancuta; Lydie Trautmann; Francesco A Procopio; Bader Yassine-Diab; Geneviève Boucher; Mohamed-Rachid Boulassel; Georges Ghattas; Jason M Brenchley; Timothy W Schacker; Brenna J Hill; Daniel C Douek; Jean-Pierre Routy; Elias K Haddad; Rafick-Pierre Sékaly
Journal:  Nat Med       Date:  2009-06-21       Impact factor: 53.440

View more
  36 in total

Review 1.  The impact of sarcopenia on survival and complications in surgical oncology: A review of the current literature.

Authors:  Savita Joglekar; Peter N Nau; James J Mezhir
Journal:  J Surg Oncol       Date:  2015-08-27       Impact factor: 3.454

Review 2.  HIV-1 transcription and latency: an update.

Authors:  Carine Van Lint; Sophie Bouchat; Alessandro Marcello
Journal:  Retrovirology       Date:  2013-06-26       Impact factor: 4.602

3.  Liposomes as nanocarriers for anti-HIV therapy.

Authors:  Shruti Chopra; Natarajan Venkatesan; Guru V Betageri
Journal:  Drug Deliv Transl Res       Date:  2013-10       Impact factor: 4.617

4.  Designed transcription activator-like effector proteins efficiently induced the expression of latent HIV-1 in latently infected cells.

Authors:  Xiaohui Wang; Pengfei Wang; Zheng Fu; Haiyan Ji; Xiying Qu; Hanxian Zeng; Xiaoli Zhu; Junxiao Deng; Panpan Lu; Shijun Zha; Zhishuo Song; Huanzhang Zhu
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

5.  Multiple low-dose challenges in a rhesus macaque AIDS vaccine trial result in an evolving host response that affects protective outcome.

Authors:  Christian Selinger; Natasa Strbo; Louis Gonzalez; Lauri Aicher; Jeffrey M Weiss; G Lynn Law; Robert E Palermo; Monica Vaccari; Genoveffa Franchini; Eckhard R Podack; Michael G Katze
Journal:  Clin Vaccine Immunol       Date:  2014-10-01

Review 6.  Therapy for latent HIV-1 infection: the role of histone deacetylase inhibitors.

Authors:  Mary E Manson McManamy; Shweta Hakre; Eric M Verdin; David M Margolis
Journal:  Antivir Chem Chemother       Date:  2014-01-29

Review 7.  The effects of cocaine on HIV transcription.

Authors:  Mudit Tyagi; Jaime Weber; Michael Bukrinsky; Gary L Simon
Journal:  J Neurovirol       Date:  2015-11-16       Impact factor: 2.643

Review 8.  Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART.

Authors:  C W Peterson; P Younan; K R Jerome; H-P Kiem
Journal:  Gene Ther       Date:  2013-01-31       Impact factor: 5.250

Review 9.  Mechanisms of HIV Transcriptional Regulation by Drugs of Abuse.

Authors:  Mudit Tyagi; Michael Bukrinsky; Gary L Simon
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

10.  AP-1 and NF-κB synergize to transcriptionally activate latent HIV upon T-cell receptor activation.

Authors:  Joseph Hokello; Adhikarimayum Lakhikumar Sharma; Mudit Tyagi
Journal:  FEBS Lett       Date:  2021-02-09       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.